CA
NZ
UK
AU
IND
US
Commodity markets possess a curious habit. They rarely wait for events to unfold before pricing them. Instead, they trade probabilities, exaggerating risks during moments of uncertainty before rapidly reversing course when catastrophe fails to materialise.
Shares ofShutterstock (NYSE: SSTK)suffered one of their steepest declines in years afterGetty Images (NYSE: GETY)officially abandoned its proposed $3.7 billion all-stock acquisition, ending what had been viewed as one of the most significant consolidation deals in the digital media industry.
• Can-Fite BioPharma Ltd. (NYSE: CANF) reported that its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint and showed durable overall survival.
• What They Are: Pre-funded warrants let investors pay for shares upfront and exercise later at a nominal price, near zero.
• $125 Million in Gross Proceeds: Neurogene (NASDAQ: NGNE) expects roughly $125 million in gross proceeds before fees and any over-allotment exercise.
• $600 Million Offering Size: Abivax (NASDAQ: ABVX) initiated a registered public offering of ADSs totaling roughly $600 million, or about €527 million.
• Up to $8.8 Million Deal: Cadrenal Therapeutics (NASDAQ: CVKD) signed a private placement of up to $8.8 million with a single healthcare-focused institutional investor.
• NYSE American Deficiency Notice: Matinas BioPharma (NYSE American: MTNB) received a June 24, 2026 notice of a continued-listing deficiency.
• All Proposals Adopted: NewcelX (NASDAQ: PUBT) shareholders voted to adopt the full suite of proposals submitted by the board.
• Two Forces at Play: Biotech sessions often pit clinical progress against capital raises, and both moved together in the latest tape.
Please wait processing your request...